Abstract:Key PointsTopoisomerase I (TOP1) enzymes are essential in higher eukaryotes, as they are required to relax DNA supercoiling generated by transcription, replication and chromatin remodelling.Topoisomerases are particularly vulnerable to topoisomerase I inhibitors during their cleavage reaction, which is referred to as the 'cleavage complex'.TOP1 can be trapped by anticancer drugs as it cleaves DNA. Moreover, TOP1 can be trapped by endogenous alterations to DNA (mismatches, abasic sites, nicks and adducts) and apoptotic alterations to chromatin.Camptothecin is a natural product of which TOP1 is the only cellular target. Two camptothecin derivatives have recently been approved by the US Food and Drug Administration: topotecan for ovarian and lung cancers and irinotecan for colorectal cancer.Various non-camptothecin inhibitors of TOP1 are in development, including indolocarbazole, phenanthridine and indenoisoquinoline derivatives. Non-camptothecins are expected to be active in cancers that are currently resistant to camptothecins, and to have a greater therapeutic index.Co-crystal structures of TOP1 inhibitors illustrate the interfacial inhibition paradigm by which a small drug molecule can trap conformational intermediates of macromolecular complexes (in the case of TOP1 inhibitors, the TOP1 enzyme and its cleaved DNA substrate).The cytotoxic activity of TOP1 inhibitors is related to the interference of trapped TOP1 cleavage complexes with DNA replication and transcription.Deficiencies in both the checkpoint and DNA-repair pathways determine cellular sensitivity to TOP1 inhibitors. Therefore, the identification of such deficiencies in tumours should guide the rational use of TOP1 inhibitors. Targeting checkpoint and repair pathways should also increase the selectivity of TOP1 inhibitors in tumours that have pre-existing deficiencies in relevant redundant pathways.

New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors

Topoisomerase I Inhibitors Derived From Natural Products: Structure-Activity Relationships And Antitumor Potency

Recent Advances in Non-camptothecin DNA Topoisomerase I Inhibitors as Anticancer Drugs

Topoisomerase I inhibitors: Challenges, progress and the road ahead

Development of Indenoisoquinoline Derivatives as Novel Topoisomerase 1 Inhibitors

Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements

Discovery of a Novel Series of Quinolone and Naphthyridine Derivatives As Potential Topoisomerase I Inhibitors by Scaffold Modification.

Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches

Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Topoisomerase I inhibitors: Review and update

Recent developments in the clinical activity of topoisomerase-1 inhibitors

Topoisomerase I inhibitors: camptothecins and beyond

Evolutionary Trace Analysis of Eukaryotic DNA Topoisomerase I Superfamily: Identification of Novel Antitumor Drug Binding Site

Discovery Of Dna Topoisomerase I Inhibitors With Low-Cytotoxicity Based On Virtual Screening From Natural Products

Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors

Synthesis Of Novel Benzoxanthone Analogues As Non-Camptothecin Topoisomerase I Inhibitors

Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide

A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade

Oral Topoisomerase 1 Inhibitors in Adult Patients: Present and Future

Advances in the Researches on Topoisomerase I Inhibitors

PROSPECTS FOR SEARCHING MULTITARGET TOPOISOMERASE INHIBITORS WITH ANTITUMOR PROPERTIES